ArticleBiomedical microdevices2026
A comparative study of COVID-19 point-of-care detection across human biofluids using MEMS-based near-infrared spectroscopy and machine learning.
Article in Biomedical microdevices, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study explores the use of near-infrared (NIR) spectroscopy in the 1.3–2.6 μm wavelength range, employing a handheld miniaturized microelectromechanical systems (MEMS)-based spectrometer for the rapid, non-invasive detection of COVID-19 from various biofluids. A total of 238 samples—including nasopharyngeal (NSP) swabs, nasal swabs, and saliva—from both COVID-19 positive and negative individuals are analysed. Machine learning algorithms process the spectral data to develop predictive models for the disease classification. Models based on a single biofluid achieve detection accuracies between 75% and 80%, while combining scans from multiple biofluids of the same individual improves accuracy to 88%. The study highlights trade-offs between sample accessibility and diagnostic performance. Overall, the findings demonstrate that NIR spectroscopy serves as a viable low-cost, portable, and rapid point-of-care (POC) solution, with strong potential for scalable mass screening—particularly in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.